Teva Pharmaceutical Industries Target of Unusually Large Options Trading (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) saw unusually large options trading on Tuesday. Traders purchased 140,688 call options on the stock. This is an increase of approximately 504% compared to the average daily volume of 23,306 call options.

Insiders Place Their Bets

In related news, EVP Christine Fox sold 19,388 shares of the stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.55% of the stock is owned by insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of large investors have recently bought and sold shares of TEVA. FMR LLC lifted its position in Teva Pharmaceutical Industries by 49.5% during the third quarter. FMR LLC now owns 62,740,763 shares of the company’s stock valued at $1,130,589,000 after buying an additional 20,762,226 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Teva Pharmaceutical Industries by 7,945.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company’s stock valued at $86,350,000 after acquiring an additional 4,732,374 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Teva Pharmaceutical Industries by 237.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,377,517 shares of the company’s stock worth $60,863,000 after purchasing an additional 2,376,668 shares during the period. Clal Insurance Enterprises Holdings Ltd increased its holdings in Teva Pharmaceutical Industries by 6.8% in the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock valued at $621,337,000 after purchasing an additional 2,204,623 shares in the last quarter. Finally, State Street Corp raised its position in Teva Pharmaceutical Industries by 10.0% in the third quarter. State Street Corp now owns 19,500,683 shares of the company’s stock valued at $351,402,000 after purchasing an additional 1,778,268 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

TEVA has been the subject of a number of analyst reports. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Barclays boosted their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. UBS Group raised their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. boosted their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and a consensus price target of $19.67.

Teva Pharmaceutical Industries Price Performance

TEVA stock traded up $4.37 on Tuesday, reaching $20.88. The company had a trading volume of 34,909,104 shares, compared to its average volume of 9,253,202. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The company’s fifty day moving average is $17.47 and its 200 day moving average is $17.40. The company has a market cap of $23.66 billion, a P/E ratio of -23.21, a PEG ratio of 0.99 and a beta of 0.79. Teva Pharmaceutical Industries has a 1 year low of $10.00 and a 1 year high of $20.89.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.